PrEP Efficacy Trial Results

STUDY POPULATION LOCATIONS REGIMEN/RESULTS iPrEx • 2,499 gay men • • Daily oral Truvada showed 44% efficacy Phase III trial that evaluated the safety and efficacy of once-daily •other MSM • •transgender • oral Truvada to prevent HIV infection in gay men, other men who women • South Africa have sex with men (MSM) and transgender women. • For more information: www.avac.org/trial/iprex •US TDF2 Study • 1,200 men •Botswana • Daily oral Truvada showed 62% efficacy and women Phase II/III trial that evaluated the safety of once-daily oral Truvada in heterosexual men and women. For more information: www.avac.org/trial/tdf2 Partners PrEP Study • 4,758 •Kenya • Daily oral Truvada showed 75% efficacy serodiscordant Phase III trial that evaluated the safety and efficacy of two different •Uganda • Daily oral tenofovir showed 67% efficacy heterosexual strategies to prevent HIV transmission in HIV-serodiscordant couples: couples once-daily oral tenofovir and once-daily oral Truvada. For more information: www.avac.org/trial/partners-prep Bangkok Tenofovir Study (CDC 4370) • 2,400 people •Thailand • Daily oral tenofovir showed 49% efficacy who inject Phase II/III trial that evaluated the safety and efficacy of once-daily drugs oral tenofovir to prevent HIV infection in people who inject drugs. For more information: www.avac.org/trial/cdc-4370-bangkok-tenofovir-study FEM-PrEP •Kenya • Daily oral Truvada showed no effect • 1,950 women • South Africa Phase III trial that evaluated the safety and effectiveness of once- •Tanzania daily oral Truvada for HIV prevention in women. For more information: www.avac.org/trial/fem-prep VOICE (MTN 003) • South Africa • Daily oral tenofovir showed no effect Phase IIb trial that evaluated the safety and effectiveness of • 5,029 women •Uganda • Daily oral Truvada showed no effect •Zimbabwe • Daily vaginal tenofovir gel showed no three different strategies to prevent HIV in women: once-daily oral effect tenofovir, oral Truvada, and vaginal tenofovir gel. For more information: www.avac.org/trial/mtn-003-voice

www.paetc.org | (415) 476-6153 HIV training and capacity building for healthcare professionals How well does PrEP work?

100% >99% >96% 90% ** 80% 85% 74% 75% 60% Poor effectiveness due to 62% very few people actually 49% 49% taking the pill as prescribed 40% 44%

20% 6% -4% 0% iPrEx OLE Bangkok VOICE FEM-PrEP Partners iPrEx TDF2 IDU* PrEP

efficacy related to overall efficacy, includes people *tenofovir only **CDC reported data, regular dosing of PrEP who took PrEP as prescribed as not statistically well as those who didn”t significant

PrEP efficacy is strongly associated with adherence.